NSABP B-42 | ESMO 2026 🎗️ 5 MORE YEARS OF LETROZOLE — WORTH IT? After 5 years of endocrine therapy, does extending letrozole improve outcomes in HR+ early breast cancer? 📉 Distant metastases at 15 years: 9.7% → 6.9% (HR 0.72) ✅ ~3 fewer distant recurrences per 100 women ❌ No significant overall survival benefit (HR 0.92) 💡 The lesson: Extended endocrine therapy is not for everyone. Individualize based on recurrence risk, bone health and tolerability. FEWER RECURRENCES. NO PROVEN OS GAIN. EXTEND SELECTIVELY! #MVOnco #ESMO2026 #BreastCancer #NSABPB42 #Letrozole @myESMO @OncoAlert @larvol

KEYNOTE-177 vs CheckMate 8HW: PD-1 alone or dual IO? Two landmark trials reshaping first-line treatment of MSI-H/dMMR metastatic colorectal cancer. 🔹 KEYNOTE-177 (André et al.) — Pembrolizumab established chemotherapy-free PD-1 monotherapy, with durable responses and a favourable toxicity profile. 🔹 CheckMate 8HW (Lonardi et al.) — Nivolumab + ipilimumab demonstrated significant survival benefit, with 5-year OS of 77% in the first-line cohort and 74% versus 62% against nivolumab across treatment lines. ⚠️ 77% vs 54.8% is NOT a head-to-head comparison! Different populations, trial designs and biomarker assessment preclude claims of superiority. The question now: Who truly needs dual IO, and who can do just as well with PD-1 monotherapy? 📚 André et al. Ann Oncol, 2025; Lonardi et al. Ann Oncol, 2026. @myESMO @OncoAlert @larvol #MVOnco #ESMO2026 #ColorectalCancer #MSIH #Immunotherapy

NeoLOCUS vs PCm/DCF | Phase II Promise vs Phase III Evidence! Two Indian studies exploring neoadjuvant strategies in oral cavity cancer. 🔹 NeoLOCUS | Marimuthu et al. Single-arm Phase II (n=34), incorporating low-dose nivolumab + chemotherapy + oral metronomic therapy. ORR 66.6% | Surgery 87.9% | 2-year OS 67.1%. 🔹 PCm vs DCF | Noronha et al. Randomized Phase III (n=475). PCm demonstrated OS non-inferiority to DCF, with higher response and surgery rates and substantially less grade ≥3 toxicity (43.2% vs 86.4%). 🎯 Take-home: PCm has randomized Phase III evidence. NeoLOCUS is promising but needs Phase III validation. ⚠️ Different populations and study designs — cross-trial comparisons are not head-to-head. References: Marimuthu et al.; Noronha et al. ESMO 2026. @myESMO @OncoAlert @larvol #MVOnco #ESMO2026 #HeadNeckCancer #OralCancer #Immunotherapy

🇮🇳 LESS TOXICITY. MORE SURGERIES. SAME SURVIVAL! An important Indian Phase III trial at #ESMO2026! DCF/TPF vs PCm in technically unresectable oral cavity cancer (n=475). 📘 PART 1 | WHY THIS TRIAL? Can weekly paclitaxel–carboplatin + oral metronomic therapy replace intensive DCF without compromising survival? 📘 PART 2 | EFFICACY ✅ OS non-inferior: HR 0.826; p=0.0002 ✅ Response: 45.6% vs 23.4% ✅ Resectability: 57.3% vs 33.9% ✅ Surgery: 45.6% vs 26% 📘 PART 3 | SAFETY ✅ Grade ≥3 toxicity: 43.2% vs 86.4% ✅ Growth-factor use: 20.5% vs 100% ✅ Outpatient-friendly, without routine infusion-pump requirements. 📘 PART 4 | THE VERDICT More responses and surgical opportunities, with substantially less toxicity — but no proven OS superiority. A compelling alternative for selected patients, not a replacement for upfront surgery in resectable disease. Less treatment burden. More surgical opportunities. 📚 Reference: Vanita Noronha et al. Multicentre Phase III randomized non-inferiority study. ESMO Congress 2026, LBA44. CTRI/2023/08/056693. @myESMO @OncoAlert @larvol #ESMO2026 #HeadNeckCancer #OralCancer #IndianOncology #MVOnco

🧬 CLARITY-Gastric01 | #ESMO2026 LBA7 A GIANT OS LEAP. A TINY PFS STEP! 4 visuals: Cartoon • Design • Efficacy • Verdict 🎯 CLDN18.2 ≥25% | Sone-Ve (MMAE ADC) 📈 3L+ OS: 10 vs 5 mo (HR 0.47) 2L+ OS: 10.6 vs 6.4 mo (HR 0.58) ⚠️ PFS: HR 0.77 — prespecified significance threshold missed! 🛡️ Grade ≥3 TRAEs: 36.4% vs 44.8% Remarkable survival benefit. But why the OS–PFS disconnect? 📚 Xu R-H et al. ESMO 2026; LBA7. @myESMO @OncoAlert @larvol #MVOnco

🇮🇳 MORE SURGERY. LESS TOXICITY. SAME SURVIVAL! DCF vs PCm | ESMO 2026 | Noronha et al. An important Indian multicentre Phase III non-inferiority trial in technically unresectable oral cavity cancer (n=475). 🎨 THE CARTOON TELLS THE STORY! 🔴 DCF — THE HEAVY ROAD - Docetaxel + Cisplatin + 5-FU - Grade ≥3 toxicity: 86.4% - Growth-factor use: 100% - Intensive, infusion-based treatment. 🟢 PCm — THE LIGHTER ROAD - Weekly paclitaxel–carboplatin + oral metronomic therapy - Grade ≥3 toxicity: 43.2% - Growth-factor use: 20.5% - Outpatient-friendly, reduced treatment burden. 🏁 SAME SURVIVAL DESTINATION! - Median OS: 13.99 vs 13.31 months - HR 0.826 | Non-inferiority p=0.0002 - Non-inferior OS — NOT proven superior. 🚪 MORE PATIENTS REACH SURGERY! - Response: 23.4% → 45.6% - Resectability: 33.9% → 57.3% - Surgery performed: 26.0% → 45.6% All comparisons: DCF → PCm. 💡 THE TAKE-HOME Two different roads. A non-inferior survival outcome. PCm delivered more responses, more surgical opportunities and approximately HALF the severe toxicity. A compelling Indian neoadjuvant alternative for selected patients — not a replacement for upfront surgery in resectable disease. 📚 Reference: Noronha V et al. ESMO 2026; LBA44. CTRI/2023/08/056693. @myESMO @OncoAlert @larvol #ESMO2026 #OralCancer #HeadNeckCancer #MedicalOncology #IndianOncology #MVOnco